Received Feb 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | TP2N2 | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
patient wanted to get a late second dose.; she ended up getting shingles,; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of shingles in a female patient who received Herpes zoster (Shingrix) (batch number TP2N2, expiry date 10-FEB-2023) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On 05-OCT-2021, the patient received the 1st dose of Shingrix. On an unknown date, the patient did not receive the 2nd dose of Shingrix. In JUL-2024, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: she ended up getting shingles,). On an unknown date, the patient experienced incomplete course of vaccination (Verbatim: patient wanted to get a late second dose.). The outcome of the shingles and incomplete course of vaccination were unknown. It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK Receipt Date: 17-JAN-2025 The pharmacist reported that a patient received the first dose of Shingrix and then patient decided she did not want the second dose. About 6 months ago she ended up getting shingles, and now patient wanted to get a late second dose. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.